Findings from our study stronglysuggest that HGSC patients can significantly benefit from treatment with STINGagonist to enhance anti-tumour immune response or overcome adaptive immuneresistance, via enhanced CD8+ TIL cross-priming postchemotherapy, when administered selectively in patients with an under-reactive TME.Since ovarian tumours responded poorly to immune checkpoint blockade, findings fromour will be foundational to the design of treatment strategies that can potentiallycombine STING agonist to enhance response. This evidence concerns the gene CD8A and ovarian neoplasm.